X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with Pfizer - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs PFIZER - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA PFIZER TORRENT PHARMA/
PFIZER
 
P/E (TTM) x 38.7 34.5 112.4% View Chart
P/BV x 6.8 5.4 125.5% View Chart
Dividend Yield % 0.7 0.6 119.8%  

Financials

 TORRENT PHARMA   PFIZER
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-18
PFIZER
Mar-18
TORRENT PHARMA/
PFIZER
5-Yr Chart
Click to enlarge
High Rs1,5502,365 65.5%   
Low Rs1,1441,625 70.4%   
Sales per share (Unadj.) Rs354.7430.3 82.4%  
Earnings per share (Unadj.) Rs40.178.7 50.9%  
Cash flow per share (Unadj.) Rs64.293.2 68.9%  
Dividends per share (Unadj.) Rs14.0020.00 70.0%  
Dividend yield (eoy) %1.01.0 103.7%  
Book value per share (Unadj.) Rs273.1586.5 46.6%  
Shares outstanding (eoy) m169.2245.75 369.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.84.6 81.9%   
Avg P/E ratio x33.625.3 132.6%  
P/CF ratio (eoy) x21.021.4 98.0%  
Price / Book Value ratio x4.93.4 144.9%  
Dividend payout %34.925.4 137.5%   
Avg Mkt Cap Rs m227,89791,271 249.7%   
No. of employees `00014.72.6 558.9%   
Total wages/salary Rs m11,3533,143 361.2%   
Avg. sales/employee Rs Th4,083.07,484.8 54.6%   
Avg. wages/employee Rs Th772.31,195.0 64.6%   
Avg. net profit/employee Rs Th461.31,369.1 33.7%   
INCOME DATA
Net Sales Rs m60,02119,685 304.9%  
Other income Rs m2,9881,143 261.5%   
Total revenues Rs m63,00920,828 302.5%   
Gross profit Rs m13,4935,003 269.7%  
Depreciation Rs m4,086663 616.8%   
Interest Rs m3,0854 73,447.6%   
Profit before tax Rs m9,3105,479 169.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,5291,878 134.6%   
Profit after tax Rs m6,7813,601 188.3%  
Gross profit margin %22.525.4 88.5%  
Effective tax rate %27.234.3 79.2%   
Net profit margin %11.318.3 61.8%  
BALANCE SHEET DATA
Current assets Rs m52,62324,167 217.7%   
Current liabilities Rs m52,0229,544 545.0%   
Net working cap to sales %1.074.3 1.3%  
Current ratio x1.02.5 39.9%  
Inventory Days Days12055 217.1%  
Debtors Days Days7629 265.6%  
Net fixed assets Rs m85,0169,514 893.6%   
Share capital Rs m846458 185.0%   
"Free" reserves Rs m45,37626,375 172.0%   
Net worth Rs m46,22226,832 172.3%   
Long term debt Rs m41,11525 164,458.4%   
Total assets Rs m142,43236,900 386.0%  
Interest coverage x4.01,305.5 0.3%   
Debt to equity ratio x0.90 95,468.8%  
Sales to assets ratio x0.40.5 79.0%   
Return on assets %6.99.8 70.9%  
Return on equity %14.713.4 109.3%  
Return on capital %14.220.4 69.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m14,58022 65,089.7%   
Fx outflow Rs m3,6001,489 241.8%   
Net fx Rs m10,980-1,466 -748.8%   
CASH FLOW
From Operations Rs m8,9423,318 269.5%  
From Investments Rs m-47,070-2,383 1,975.2%  
From Financial Activity Rs m34,174-1,104 -3,096.9%  
Net Cashflow Rs m-3,655-169 2,169.1%  

Share Holding

Indian Promoters % 71.5 0.0 -  
Foreign collaborators % 0.0 63.9 -  
Indian inst/Mut Fund % 7.0 7.5 93.6%  
FIIs % 12.6 4.9 257.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 23.7 37.1%  
Shareholders   26,511 85,207 31.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   ORCHID PHARMA LTD  CIPLA  JUBILANT LIFE SCIENCES  VENUS REMEDIES  STERLING BIOTECH  

Compare TORRENT PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Get Ready for Record Highs(Podcast)

Globally, Traders were left scrambling after the Federal Reserve forecast zero interest-rate hikes this year and just one in 2020.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 324.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended December 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 324.1% YoY). Sales on the other hand came in at Rs 21 bn (up 38.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

PFIZER Announces Quarterly Results (3QFY19); Net Profit Up 51.2% (Quarterly Result Update)

Jan 25, 2019 | Updated on Jan 25, 2019

For the quarter ended December 2018, PFIZER has posted a net profit of Rs 1 bn (up 51.2% YoY). Sales on the other hand came in at Rs 5 bn (up 12.5% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER 2017-18 Annual Report Analysis (Annual Result Update)

Jan 1, 2019 | Updated on Jan 1, 2019

Here's an analysis of the annual report of PFIZER for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PFIZER. Also includes updates on the valuation of PFIZER.

PFIZER Announces Quarterly Results (2QFY19); Net Profit Down 13.8% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, PFIZER has posted a net profit of Rs 958 m (down 13.8% YoY). Sales on the other hand came in at Rs 5 bn (down 9.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 12.3% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 12.3% YoY). Sales on the other hand came in at Rs 19 bn (up 32.5% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

More Views on News

Most Popular

My Top 3 Defence Stocks to Buy Now(The 5 Minute Wrapup)

Mar 19, 2019

The urgency to privatise India's defence sector to make India self-reliant was never as strong as it is today.

5 Fundamentally Strong Stocks to Pick for Trading Today(Profit Hunter)

Mar 15, 2019

5 fundamentally strong stocks one could buy to trade in this market right now. Make sure you grab the chance this strongly rallying market offers.

This Small Cap Stock Could Offer Triple Digit Gains from its Current Price(Profit Hunter)

Mar 19, 2019

If you are still waiting for signals, remember, there is no correct timing, only right time to Buy stocks. For select small caps, that time is now.

Elections Don't Matter!(The Honest Truth)

Mar 13, 2019

Ajit Dayal shows us why from the point of view of the Indian economy, elections don't matter.

Two Growth Stocks that Doubled in a Little Over 12 Months!(The 5 Minute Wrapup)

Mar 13, 2019

The elements that fueled profit growth for these two companies led to a surge in their stock prices.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Mar 22, 2019 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 8-QTR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS